 Novel classes antimicrobials needed address emergence multidrug-resistant bacteria methicillin-resistant Staphylococcus aureus (MRSA). recently identified pyruvate kinase (PK) potential novel drug target based upon essential hub MRSA interactome (Cherkasov, A., Hsing, M., Zoraghi, R., Foster, L. J., See, R. H., Stoynov, N., Jiang, J., Kaur, S., Lian, T., Jackson, L., Gong, H., Swayze, R., Amandoron, E., Hormozdiari, F., Dao, P., Sahinalp, C., Santos-Filho, O., Axerio-Cilies, P., Byler, K., McMaster, W. R., Brunham, R. C., Finlay, B. B., Reiner, N. E. (2011) J. Proteome Res. 10, 1139-1150; Zoraghi, R., See, R. H., Axerio-Cilies, P., Kumar, N. S., Gong, H., Moreau, A., Hsing, M., Kaur, S., Swayze, R. D., Worrall, L., Amandoron, E., Lian, T., Jackson, L., Jiang, J., Thorson, L., Labriere, C., Foster, L., Brunham, R. C., McMaster, W. R., Finlay, B. B., Strynadka, N. C., Cherkasov, A., Young, R. N., Reiner, N. E. (2011) Antimicrob. Agents Chemother. 55, 2042-2053). Screening extract library marine invertebrates MRSA PK resulted identification bis-indole alkaloids spongotine (A), topsentin (B, D), hamacanthin (C) classes isolated Topsentia pachastrelloides novel bacterial PK inhibitors. compounds potently selectively inhibited MRSA PK enzymatic activity S. aureus growth vitro. active compounds, cis-3,4-dihyrohyrohamacanthin B (C) bromodeoxytopsentin (D), identified highly potent MRSA PK inhibitors (IC(50) values 16-60 nM) least 166-fold selectivity human PK isoforms. novel anti-PK natural compounds exhibited significant antibacterial activities S. aureus, including MRSA (minimal inhibitory concentrations (MIC) 12.5 6.25 mug/ml, respectively) selectivity indices (CC(50)/MIC) >4. also report discrete structural features MRSA PK tetramer determined x-ray crystallography, suitable selective targeting bacterial enzyme. co-crystal structure compound C MRSA PK confirms latter target bis-indole alkaloids. elucidates essential structural requirements PK inhibitors "small" interfaces provide tetramer rigidity efficient catalytic activity. results identified series natural products novel MRSA PK inhibitors, providing basis development potential novel antimicrobials.